VIR Stock: Price, Earnings History and SEC Filings
Vir Biotechnology, Inc. (VIR) last traded at $11.30, down 3.83% on the latest session and up 1.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.47 against an analyst estimate of $0.83, a miss of 43.4%.
$11.30 -3.83%
1 month+1.07%
52-week high$12.19
52-week low$4.82
Volume1.27M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VIR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.47 | $0.83 | -43.37% |
| Dec 2025 | Feb 23, 2026 | $-0.31 | $-0.42 | +26.19% |
| Sep 2025 | Nov 5, 2025 | $-1.17 | $-0.70 | -67.14% |
VIR beat the analyst EPS estimate in 1 of its last 3 reported quarters. Source: Nasdaq.
Latest SEC filings for VIR
SEC filing data is not available right now. You can search for VIR on SEC EDGAR.
VIR news
- Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Oct 29, 2026 · finance.yahoo.com
- Which Is a Better Investment, ADMA Biologics, Inc. or Vir Biotechnology, Inc. Stock?Oct 28, 2026 · aaii.com
- Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of DirectorsOct 28, 2026 · finance.yahoo.com
- Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This QuarterOct 27, 2026 · seekingalpha.com
- Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal?Oct 27, 2026 · finance.yahoo.com
- Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial ResultsOct 21, 2026 · finance.yahoo.com
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) is a US-listed public company on Nasdaq.